• The New Money
  • Posts
  • A New Billion Dollar Psychedelic Drug, Another Solana Stacker Hits Nasdaq, And Tanbreez Inks Rare Earth Feedstock Deal

A New Billion Dollar Psychedelic Drug, Another Solana Stacker Hits Nasdaq, And Tanbreez Inks Rare Earth Feedstock Deal

The markets and trends that matter, made simple. Discover what’s next.

August 26, 2025

AbbVie Is Spending A Billion Dollars To Buy A Psychedelic Drug

AbbVie (NYSE: ABBV) struck a new deal with psychedelic drug development company Gilgamesh Pharmaceuticals to acquire their novel serotonergic psychedelic drug Bretisilocin for $1.2 billion. Gilgamesh Pharmaceuticals' Phase II clinical trials for Bretisilocin have showed significant validation for Bretisilocin to effectively treat individuals with major depressive disorder.

There's A New Nasdaq Company Coming To Stack Solana

Sharps Technology (NASDAQ: STSS) raised $400 million in a new equity financing round for the sole purpose of accumulating Solana to hold directly as an asset. Multiple notable crypto venture capital funds participated in the new funding round, including ParaFi, Pantera Capital, FalconX, Monarq and others.

Ucore And Critical Metals Cut Heavy Rare Earth Feedstock Deal

Ucore Rare Metals (TSXV: UCU) and Critical Metals (NASDAQ: CRML) entered into a new deal in which Critical Metals will supply Ucore Rare Metals with heavy rare earth element feedstock from their flagship Tanbreez project located in Greenland. This is the first ever supply deal Critical Metals has done leveraging their Tanbreez project, which is widely considered to be one of the world’s largest potential deposits of rare earth elements.

The New Money App has officially launched. Discover the world’s most exciting stocks, easier than ever before.

The Sprint

Looking to connect? Reach out and get in touch.

New here? Join our community of 100,000+ individuals interested in uncovering the world’s most exciting early stage companies.

Disclaimer: The New Money provides background information on early stage companies from publicly available sources. The New Money provides no advice on dealing in securities, is not a financial adviser and does not pretend to be so. This message is meant for information and educational purposes only. The information contained in this email is not to be considered factual or complete. Anybody interested in obtaining financial and other information on companies mentioned is advised to get it direct from the companies, or from their own investment adviser. The New Money does not intend for this information to be used to inform an investment decision. The New Money has been compensated by some of the companies mentioned in this email for awareness campaigns, which affects our ability to be unbiased. The Principals of The New Money may buy or sell shares of the mentioned companies without further notice. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. The New Money and its principals and agents are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Always do your own research and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy or Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.